Article Text

Download PDFPDF

1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.